Pakistan’s federal cabinet has approved a five-year exemption for importing unregistered lifesaving drugs for hospitals and institutions. This move ensures uninterrupted access to critical therapies, including anti-cancer and cardiac medicines. Many of these drugs are not commercially viable for local production. The exemption aims to address urgent healthcare needs while maintaining strict regulatory oversight to ensure patient safety.
Strict Import Conditions Apply
Under the exemption, imports will only be permitted with prior licensing authority. These drugs will not be available for public sale. Strict conditions, including WHO pre-qualification or approval from recognized global regulators, will apply. This ensures that only high-quality, safe medications reach patients. The decision reflects Pakistan’s commitment to improving healthcare access while adhering to international standards.
Global Practices and Legal Framework
During the cabinet meeting, the NHSR&C Division highlighted global practices, noting that access to unapproved therapies is common worldwide. The WHO’s Global Benchmarking Tool supports such exemptions. Pakistan’s Drugs Act, 1976, prohibits unregistered drug imports under Section 23(1)(a)(vii). However, Section 36 allows exemptions in the public interest, enabling this critical policy shift to save lives.
Replacement of Expired Exemption
The previous exemption, granted via SRO 134(1)/2021, expired on January 21, 2025. Following DRAP’s 198th meeting on January 27, the cabinet extended the exemption for another five years. This ensures continuity in the supply of essential medicines. The decision underscores the government’s responsiveness to healthcare challenges and its focus on patient welfare.
Also Read: Punjab Announces New School Opening Date After Summer Vacation Extension
Regulatory Requirements for Imports
Imported drugs must be approved for free sale in their country of origin. Vaccines and antisera require WHO pre-qualification or other recognized global approvals. These medications can only be used for therapeutic purposes within hospitals and institutions. They cannot be utilized for clinical trials, testing, or retail sales, ensuring controlled and safe usage under medical supervision.
Quality Assurance and Record-Keeping
Importers must obtain clearance certificates upon shipment arrival. They are also required to maintain detailed consumption records under a qualified person’s supervision. These measures prevent misuse and ensure accountability. By enforcing strict documentation, the government aims to maintain transparency and safeguard patient health throughout the supply chain.
Local Manufacturing Challenges
The cabinet noted that limited patient demand makes local manufacturing unfeasible for many lifesaving drugs. Importing these medications remains the only viable solution to meet urgent healthcare needs. This exemption bridges the gap, ensuring patients receive necessary treatments without delays. The decision highlights the government’s pragmatic approach to addressing healthcare infrastructure limitations.
Benefits for Patients with Critical Conditions
This policy is expected to benefit patients with life-threatening conditions by ensuring a steady supply of otherwise unavailable treatments. Hospitals and institutions can now access essential drugs without regulatory hurdles. The move aligns with global healthcare standards, offering hope to countless patients relying on specialized therapies for survival.
Conclusion: A Step Toward Better Healthcare
The cabinet’s approval of the five-year exemption reflects a proactive approach to healthcare challenges. By facilitating imports of unregistered lifesaving drugs, Pakistan ensures patients receive timely, quality treatments. Strict regulations maintain safety, while the exemption addresses gaps in local production. This decision marks a significant milestone in improving healthcare accessibility for vulnerable populations across the country.
